A First in Human Study of ALX2004 With Advanced or Metastatic Selected Solid Tumors
NCT07085091
This study is recruiting at 11 US sites in 9 states, according to its ClinicalTrials.gov record last updated .
Summary
A Phase 1, First in Human, Open-Label Multicenter Study to Evaluate ALX2004, an Antibody Drug Conjugate Targeting EGFR in Participants with Advanced or Metastatic Select Solid Tumors
Shortened from the sponsor's brief summary. View official record on ClinicalTrials.gov
Conditions studied
- NSCLC (Advanced Non-small Cell Lung Cancer)
- HNSCC
- CRC (Colorectal Cancer)
- ESCC
- Colo-rectal Cancer
- Head and Neck Cancer
- Esophageal Squamous Cell Carcinoma (ESCC)
Eligibility basics and study details
- Study type
- Interventional
- Phase
- Phase 1
- Ages
- 18 years and older
- Sex
- All
- Healthy volunteers
- Not accepted
- Sponsor
- ALX Oncology Inc.
- Last updated on ClinicalTrials.gov
- September 30, 2026
These are the basic criteria only. The full inclusion and exclusion criteria are on the official record, and the study team decides who can take part.
US recruiting sites
California · 2
- ALX Center 9 · La Jolla, CA
- ALX Center 11 · Santa Monica, CA
Florida · 1
- ALX Center 7 · Tampa, FL
Michigan · 2
- ALX Center 8 · Farmington Hills, MI
- ALX Center 3 · Grand Rapids, MI
New Jersey · 1
- ALX Center 12 · Morristown, NJ
Ohio · 1
- ALX Center 10 · Columbus, OH
Oregon · 1
- ALX Center 6 · Portland, OR
Texas · 1
- ALX Center 5 · Houston, TX
Utah · 1
- ALX Center 4 · West Valley City, UT
Virginia · 1
- ALX Center 2 · Fairfax, VA
Source: ClinicalTrials.gov, data processed . Recruiting US sites filtered by distance and site status; summaries shortened.